The U.S. Food & Drug Administration approved Hemgenix in 2022.It's the first gene therapy for hemophilia B and its use is expected to continue to grow. "There continues to be engagement from ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, ...

J.R. Landry became one of only a handful in the nation, and the first in Rhode Island, to get what doctors believe will be ...

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday. The data comes months after the ...

The first patient in the UK has been treated by the NHS with CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene ...

Changing how biopharmas package their products, how regulators review new drugs and how mutated genes are fixed could make ...

A 44-year-old man with haemophilia B has just received the world’s most expensive drug—on the NHS. Costing £2.6 million per ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

A 44-year-old man has just become the first person to receive the world’s most expensive drug—right here on the NHS. Hemgenix ...